Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 17/20 | 0.71 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.60 |
| ▸ | RXRA | P19793 | 1/20 | 0.56 |
| ▸ | RXRB | P28702 | 1/20 | 0.56 |
| ▸ | RXRG | P48443 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | IDO1 | P14902 | 1/20 | 0.52 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5102961 | 0.86 | PTGER1 (0.57) | PTGER1TBXA2RCYP2C9CYP3A4IDO1 | |
| SCHEMBL5096132 | 0.83 | PTGER1 (1.00) | PTGER1CYP2C9RXRARXRBRXRG | |
| SCHEMBL14038957 | 0.83 | PTGER1 (0.49) | PTGER1TBXA2RCYP2C9 | |
| SCHEMBL5099618 | 0.81 | RXRA (0.78) | PTGER1CYP2C9RXRARXRBRXRG | |
| SCHEMBL4886674 | 0.80 | PTGER1 (0.79) | PTGER1TBXA2RCYP2C9RXRARXRB | |
| SCHEMBL5099974 | 0.80 | PTGER1 (1.00) | PTGER1CYP2C9RXRARXRBRXRG | |
| SCHEMBL4914145 | 0.78 | PTGER1 (0.74) | PTGER1TBXA2RCYP2C9CYP3A4 | |
| SCHEMBL5619983 | 0.78 | PTGER1 (0.77) | PTGER1TBXA2RCYP2C9CYP3A4 | |
| SCHEMBL5100875 | 0.78 | PTGER1 (1.00) | PTGER1TBXA2RCYP2C9CYP3A4 | |
| SCHEMBL31418173 | 0.77 | PTGER1 (0.54) | PTGER1TBXA2RCYP2C9CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070225340-A1 | Phenyl Compounds And Their Use In The Treatment Of Conditions Mediated By The Action Of Pge2 At The Ep1 Receptor | GLAXO GROUP LIMITED (GB) | 2007-09-27 | — | — | US | claimed |
| US-7446222-B2 | Phenyl compounds | GLAXO GROUP LIMITED (GB) | 2008-11-04 | — | — | US | disclosed |
| US-7446222-B2 | Phenyl compounds | GLAXO GROUP LIMITED (GB) | 2008-11-04 | — | — | US | disclosed |
| US-20070225340-A1 | Phenyl Compounds And Their Use In The Treatment Of Conditions Mediated By The Action Of Pge2 At The Ep1 Receptor | GLAXO GROUP LIMITED (GB) | 2007-09-27 | — | — | US | disclosed |
| EP-1742916-A1 | PHENYL COMPOUNDS AND THEIR USE IN THE TREATMENT OF CONDITIONS MEDIATED BY THE ACTION OF PGE2 AT THE EP1 RECEPTOR | GLAXO GROUP LIMITED (GB) | 2007-01-17 | — | — | EP | disclosed |
| US-20060235057-A1 | Phenyl compounds | GLAXO GROUP LIMITED (GB) | 2006-10-19 | — | — | US | disclosed |
| WO-2005108369-A1 | PHENYL COMPOUNDS AND THEIR USE IN THE TREATMENT OF CONDITIONS MEDIATED BY THE ACTION OF PGE2 AT THE EP1 RECEPTOR | GLAXO GROUP LIMITED (GB) | 2005-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225340-A1 | Phenyl Compounds And Their Use In The Treatment Of Conditions Mediated By The Action Of Pge2 At The Ep1 Receptor | PTGER1, PTGER2, PTGDR | PTGER1 1/4885TBXA2R 11/4885CYP2C9 223/4885 |
| US-20060235057-A1 | Phenyl compounds | RXRB, CYP2C9, RXFP1 | PTGER1 504/4885TBXA2R 36/4885CYP2C9 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.